GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SciVision Biotech 1786.TW · TWD

Health Care · Taiwan Stock Exchange · 🇹🇼 Taiwan

Compare

51.10

+8.61%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About SciVision Biotech

Its shares trade on Taiwan Stock Exchange under the ticker 1786.TW. It has been listed since 29 December 2010. In the fiscal year to 31 December 2025, it reported revenue of TWD 886.6m and net income of TWD 162.3m. At that date it held total assets of TWD 2.67bn and shareholders' equity of TWD 1.98bn.

SciVision Biotech, Inc. engages in the research, development, and production of hyaluronic acid medical products. The company is headquartered in Kaohsiung, Kaohsiung. The company went IPO on 2010-12-29. The firm primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The firm is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The firm operates its business in the Americas, Europe, Asia, Middle East and Africa.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
29 Dec 2010

Leadership

Pay as last reported

  • Kaicheng HanChairman of the Board, General Manager, since 2002
  • Zongwei PanDeputy General Manager, Director, since 2020
  • Ruling GuoDeputy General Manager, Head of Finance & Accounting
  • Huiwen XuCorporate Governance Officer
  • Guojian FangDirector
  • Taiwei HanDirector
  • Jieqing HuangDirector
  • Minggong YangDirector
  • Shulan Yang LiDirector
  • Rongchao ChenIndependent Director
  • Mr. Shuicong ChenIndependent Director
  • Mr. Zugang LeiIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • SciVision Biotech produces hyaluronic acid medical products for global markets.
  • The firm provides subcutaneous fillers for plastic surgery facial injection.
  • SciVision Biotech manufactures hyaluronic acid raw materials for various industries.

Weaknesses

  • The company is headquartered in Kaohsiung, which may limit local talent.
  • SciVision Biotech operates in multiple regions, increasing operational complexity.
  • The firm engages in DNA identification, which requires specialized expertise.

Opportunities

  • SciVision Biotech expands joint cavity injections for orthopedics use globally.
  • The firm provides care products and foods to new customers.
  • SciVision Biotech offers DNA sequencing and application services worldwide.

Threats

  • SciVision Biotech faces competition in the hyaluronic acid medical products sector.
  • The firm operates in the Americas, Europe, Asia, Middle East and Africa.
  • SciVision Biotech must maintain quality in DNA identification and detection.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.